Skip to content

Generate Biomedicines, Inc. GENB Increase (Decrease) in Other Operating Assets

Increase (Decrease) in Other Operating Assets at other companies

MYR Group logo
MYR GroupMYRG
-$2.96M+68.9%
NNN REIT logo
NNN REITNNN
$792K+160%
Piper Sandler logo
Piper SandlerPIPR
$2.66M-96.0%
LKQ logo
LKQLKQ
$23M+91.7%
CHE
ChemedCHE
$3.6M+219%
Celanese Corporation logo
Celanese CorporationCE
$18M+124%

Other financials

Income statement

See full
Revenue$7.2M-18.1%
Operating income-$64.1M-33.1%
Net income-$61.4M-47.4%
EPS (diluted)-$1.07+34.0%

Balance sheet

See full
Cash & equivalents$160.6M-27.2%
Total debt$65.6M
Total equity$514.8M+209%
Total assets$625.7M

Cash flow

See full
Operating cash flow-$80.4M-51.2%
CapEx$3.8M+403%
Free cash flow-$84.2M-56.1%

Valuation

See full
Market cap$1.86B
Enterprise value$1.76B

Returns & leverage

See full
Debt / equity0.1×
Current ratio9.2×

Where this comes from

Reported directly by Generate Biomedicines, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherOperatingAssets.

The official record: Generate Biomedicines, Inc. ’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Generate Biomedicines, Inc. 's increase (decrease) in other operating assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Generate Biomedicines, Inc. 's increase (decrease) in other operating assets?
Generate Biomedicines, Inc. (GENB) reported increase (decrease) in other operating assets of -$2.05M in Q1 2026.
What does increase (decrease) in other operating assets mean?
This captures the net change in miscellaneous assets that are not classified as loans, securities, or property, plant, and equipment. It often includes items like accrued interest receivables, prepaid expenses, and other short-term operational assets.